Trade Nektar Therapeutics - NKTR CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.23
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021485 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02149%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000738 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021485 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000738 %
  (-$0.01)

Key Stats

• Prev. Close: 70.58
• Open: 70.86
• 1-Year Change: 48.22%
• Day's Range: 68.41 - 70.86

Trade Nektar Therapeutics - NKTR

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Nektar Therapeutics revenues decreased 33% to $101.9M. Net loss increased 18% to $523.8M. Revenues reflect United States segment decrease of 84% to $10.1M. Higher net loss reflects Non-cash interest expense on liabilities increase of 56% to $47.3M (expense), Interest income and other income (expens decrease of 86% to $2.6M (income).

Equity composition

Common Stock $.0001 Par, 04/11, 300M auth., 114,073,353 issd.Insiders own 0.39% . IPO: 5/94,2.15M shares @ $7.50 by Lehman Brothers. PO 12/97, 1.725Mshares @ $24.875 by Lehman Brothers. *NOTE: 2/97, 1.8M shsissued in private placement @ $18/shs. 8/00, 2-for-1 stock split. Sr B Conv. Pfd. $0.0001 Par, 0 o/s.